Metabolomic profiling reveals potential biomarkers in esophageal cancer progression using liquid chromatography-mass spectrometry platform
Metabolomic profiling reveals potential biomarkers in esophageal cancer progression using liquid chromatography-mass spectrometry platform
复制标题
使用液相色谱-质谱平台进行代谢组学分析揭示食管癌进展的潜在生物标志物
DOI：
10.1016/j.bbrc.2017.07.060
复制
发表时间：
2017-09-09
影响因子：
3.1
通讯作者：
Sheyhidin, Ilyar
中科院分区：
文献类型：
--
作者：
Zhang, Haiping;Wang, Lei;Sheyhidin, Ilyar
食管癌是最常见的恶性肿瘤之一，预后差。代谢组学已被证明是一种强有力的方法，发现潜在的生物标志物，为癌症的诊断和预后。本研究的目的是筛选早期诊断和预后的潜在生物标志物。本研究采用液相色谱-质谱联用技术（LC-MS）对40例食管鳞状细胞癌（ESCC）患者的组织样本和相应的对照样本进行了代谢组学分析。选择了20种潜在的诊断生物标志物。9种代谢产物与肿瘤局部浸润、淋巴结转移、术后生存时间等病理特征密切相关。谷氨酸与肿瘤局部浸润有关，油酸、LysoPC（15：0）、尿嘧啶、肌苷、胆碱与淋巴结转移密切相关，而谷氨酰胺、犬尿氨酸、丝氨酸、尿嘧啶与术后生存时间有关。结果表明，代谢组学发现的潜在生物标志物能够反映食管鳞癌的代谢特征，为食管鳞癌的早期诊断、评估和预后提供了新的方法。(C)2017爱思唯尔公司All rights reserved.
Esophageal cancer (EC) is one of the most common malignancies with poor prognosis. Metabolomics has been shown to be a powerful approach to discover the potential biomarkers for cancer diagnosis and prognosis. The goal of this study is to screen potential biomarkers for early diagnosis and prognosis. In this study, 40 tissue samples and the corresponding control samples from the same esophageal squamous cell carcinoma (ESCC) patients were analyzed by liquid chromatography-mass spectrometry (LC-MS)-based metabolomics. 20 potential diagnostic biomarkers were selected. Moreover, 9 metabolites were found to be closely correlated with the pathological feature such as local invasion, lymphatic metastasis and postoperative survival time. Glutamate was correlated with local invasion of tumor, and oleic acid, LysoPC(15:0), uracil, inosine and choline were closely related with the lymphatic metastasis, while glutamine, kynurenine, serine and uracil were related with postoperative survival time. The results indicated that the potential biomarkers discovered by metabolomics could reflect the metabolic characterization of ESCC, and offers a novel approach for early diagnosis, assessment and prognosis of the disease. (C) 2017 Elsevier Inc. All rights reserved.